Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Nosocomialinfections 2018

Sessions & Tracks

Track 1: Nosocomial Infections
A nosocomial infection is contracted because of an infection or toxin that exists in a certain location, such as a hospital. Nosocomial Infections are one of the major complications for health care professionals to tackle. Every day they results in prolonged hospital stays, long-term disability, and increased resistance of microbes to antimicrobials, additional costs for healthcare systems, high costs for patients and their family, and unnecessary deaths

  • Infections in dialysis patients
  • Infections in obstetrics and gynaecology patients
  • Infections in oncology patients
  • Infections in immunocompromised hosts
  • Infections in patients with renal, liver, CNS diseases
  • Infections in transplant patients
  • Infections in intensive care units
  • Factors leading to emergence of nosocomial Infection
  • Infections in tracheostomy patients

Track 2: Healthcare-associated Infections

Healthcare-associated infections (HAIs) refer to infections associated with the delivery of healthcare in hospitals, long-term care facilities, ambulatory settings, home care and other settings.  These unanticipated infections that develop during the course of medical or surgical treatment may result in significant patient illnesses and deaths (morbidity and mortality); prolong the duration of hospital stays; and necessitate additional diagnostic and therapeutic interventions, which generate added costs.

  • Catheter-associated urinary tract infection (CAUTI)
  • Central line-associated bloodstream infection (CLABSI)
  • Ventilator-associated events
  • Chronic Obstructive Pulmonary Disease

Track 3: Surgical Site Infection (SSI)

A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material. The causative pathogens depend on the type of surgery; the most commonly isolated organisms are Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp. and Escherichia coli.

  • surgical wound infections
  • Wound dressings
  • Clinical care standards in surgery
  • Advances in invasive surgery to prevent infections

Track 4: Urinary Tract Infections

A urinary tract infection (UTI) is an infection involving any part of the urinary system, including urethra, bladder, ureters, and kidney. UTIs are the most common type of healthcare-associated infection. Among UTIs acquired in the hospital, approximately 75% are associated with a urinary catheter, which is a tube inserted into the bladder through the urethra to drain urine.

  • Catheter-associated Urinary Tract Infections (CAUTI)
  • Health Care–Acquired Urinary Tract Infection
  • Nosocomial urinary tract infection
  • Infection rate of Indwelling urethral catheter

Track 5: Ventilator-associated pneumonia

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are important causes of morbidity and mortality, with mortality rates approaching 62%. HAP and VAP are the second most common cause of nosocomial infection overall, but are the most common cause documented in the intensive care unit setting. In addition, HAP and VAP produce the highest mortality associated with nosocomial infection.

  • Mycoplasma Pneumonia
  • Bacterial Pneumonia
  • Viral Pneumonia
  • Community-acquired pneumonia
  • Respiratory disorders and Infections

Track 6: Blood Stream Infections/Bacteraemia

Blood Infections or Bacteraemia or Sepsis occurs when a bacterial infection occur somewhere else in the body such as in the lungs or skin which enters the blood stream. This is dangerous because bacteria and their toxins can be transported through the bloodstream to the entire body.

  • Central Line-associated Bloodstream Infection
  • Hospital-Acquired Bloodstream Infections
  • Nosocomial bloodstream infections
  • Prevention of  Blood Stream Infections
  • Diabetic foot ulcer

        Track 7: Infection Prevention and Control

Effective infection prevention and control is central of providing high quality health care for patients and a safe working environment for those that work in healthcare settings. It is important to minimize the risk of spread of infection to patients and staff in hospital by implementing good infection control program.

  • Decontamination and sterilization
  • Cleaning of the hospital environment
  • Disinfection of patient equipment
  • Operating room environment and Operating room staff

Track 8: Device-Associated Infections and Microbial Biofilms

Medical devices are responsible for a large portion of nosocomial infections, particularly in critically ill patients. Device associated infections can cause major medical and economic sequelae. Bacterial colonization and biofilm formation around the indwelling device can be a prelude to both infection and malfunction of the device.

  • Resistance and Tolerance of Biofilms to Antibiotics
  • Biofilm-Based Infections
  • Biofilm-Specific Antibiotic Resistance
  • Catheter related blood stream infection
  • Foreign-body and implant infections
  • Catheter related urinary tract infection
  • Innovative approaches for the prevention of device-related infections
  • Antiseptic-Coated Catheters

 Track 9: Emerging infectious diseases

An emerging infectious disease (EID) is an infectious disease whose incidence has increased in the past 20 years and could increase in the near future. some of the infectious diseases which can be commonly seen in the hospitals are Norovirus, Mycobacterium abscessus, Klebsiella, Influenza , Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococci, Tuberculosis, Vancomycin-intermediate or Vancomycin-resistant Staphylococcus aureus, Staphylococcus aureus.

  • Bacterial infections: Gram-negative
  • Bacterial infections: Gram-positive
  • Viral infections
  • Fungal infections
  • Zoonotic infections
  • Malarial drug resistance
  • Influenza A (H1N1) virus
  • Multidrug resistant tuberculosis

Track 10: Vaccines and Immunization

Immunization is a highly effective public health measure that reduces the incidence of infectious diseases, yet there has been relatively little effort toward the development of vaccines for nosocomial infections. Many nosocomial infections originate on mucosal surfaces (e.g., respiratory or gastrointestinal mucosa). As patients who are hospitalized once are more likely to be hospitalized again, a prime-boost immunization strategy, whereby a priming dose of vaccine for a nosocomial infection is administered mucosally.

  • Innovations in development of vaccines
  • Current clinical practices on vaccination
  • Immunization of health-care workers
  • Role of vaccination in healthcare systems
  • Immune enhancement and genetic studies
  • Criteria for vaccination and immunization schedule
  • Recommendations of vaccines in immunocompromised patients
  • Current clinical practices on vaccination

Track 11: Antimicrobial/ Antibiotic/ Antibacterial Resistance

Antimicrobial/ Antibiotic/ Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. Antibiotic resistance occurs when an antibiotic has lost its ability to effectively control or kill bacterial growth; in other words, the bacteria are "resistant" and continue to multiply in the presence of therapeutic levels of an antibiotic.

  •  Infections and resistance mechanisms of pathogens
  •  Surveillance of antimicrobial use and resistance
  •  Emerging issues in antibiotic resistance
  •  Prevalence of Multidrug-Resistant Organisms
  •  Genetic and physiological adaptation to the host
  •  Evolving microbes and resistant infections
  •  Immunology of Infectious Diseases
  •  Methicillin-resistant Staphylococcus aureus (MRSA)

Track 12: Antibiotics and Antimicrobial Use:

Antibiotics are used to treat or prevent some types of bacterial infection. They work by killing bacteria or preventing them from reproducing and spreading. They are often unnecessarily prescribed for viral infections, against which they have no effect. Not only antibiotics, other antivirals and antimicrobials are losing their effectiveness due to their irrational use and causing antimicrobial resistance.

  • Novel antibiotics, spectrum of activity and their applications
  • Antimicrobial Stewardship
  • Antibiotic use and its relation to the emergence of resistant bacteria
  • Pharmacokinetics and pharmacodynamics
  • Antibiotic Heterogeneity and Antibiotic Cycling
  • Monoclonal antibody as an anti-infective
  • Antibiotic susceptibility testing
  • Optimizing antibiotic usage in hospitals

Track 13: Occupational Health hazards and safety

Biological agents, including microorganisms and toxins produced by living organisms, can cause health problems in workers. Influenza is an example of a biohazard which affects a broad population of workers. Occupational illness results from exposure in a workplace to a physical, chemical or biological agent to the extent that the normal physiological mechanisms are affected and the health of the worker is impaired.

  • Identifying and handling biological agent threats
  • Occupational health hazards and illnesses
  • Microbiology of the built environment
  • Domestic and Indoor Microbiology
  • Contamination and cross contamination on hospital surfaces and medical equipment

Track 14: Pharmaceutical Microbiology

Pharmaceutical Microbiology is an applied branch of Microbiology. It involves the study of microorganisms associated with the manufacture of pharmaceuticals. pharmaceutical microbiology include the research and development of anti-infective agents, the use of microorganisms to detect mutagenic and carcinogenic activity in prospective drugs, and the use of microorganisms in the manufacture of pharmaceutical products.

  • Microbial and Biochemical Technology
  • Antimicrobial Effectiveness Testing
  • Bacterial Endotoxin Testing
  • Microbial Examination of Non-Sterile Products
  • Microbes and Environmental Management
  • Strategies to prevent microbial contamination
  • Sterile Pharmaceutical Manufacturing
  • Wastewater treatment and bio solids reuse

Track 15: Therapeutic Approaches

Nosocomial infections are a major challenge for patient safety. Empirical antibiotic therapy should be based on thorough clinical evaluation and local epidemiological data on potential pathogens and susceptibility to antibiotics. The chosen therapy must be effective, limit the toxicity and be the narrowest spectrum possible. The choice of parenteral, oral or topical antibiotic formulations is made on the basis of clinical presentation (site and severity of infection).

  • Evidence-Based Medicine
  • Advances in treatment of persistent nosocomial infections
  • Current and Future Treatment of Nosocomial Infections
  • Critical Care
  • Medical Care
  • Surgical Care
  • Wound Care
  • Monoclonal Antibody as an Anti-Infective
  • Research on antibiotic treatment and antibiotic de-escalation
  • Modification of Empiric Antibiotic Regimens
  • Appropriate Antibiotic Selection and Adequate Dosing
  • Novel Therapeutic Strategies


Market Analysis Report

Nosocomial infections or hospital acquired bacterial infections are type of infections commonly caused by bacterial pathogens and are acquired in healthcare facilities or hospitals. These pathogens should be examined in all patients who have developed some kind of clinical deterioration unexplained during the initial diagnosis. Currently, HAI market is a lucrative market venture due to increasing incidence rate of hospital acquired infections, which makes this industry a highly profitable and attractive market.

The following are the types of hospital acquired bacterial infections:

  • Urinary Tract Infections (UTI)
  • Pneumonia
  • Blood Stream Infections (BSI)
  • Surgical Site Infections


2nd International Congress on Nosocomial and Healthcare Associated Infections is an exciting opportunity for Healthcare professionals, doctors, students and pharmaceutical industries to showcase the new technology treatment in ICUs, the new products of your company, and/or the service your industry may offer to a broad international audience.

                                                     Global Market Research Report

The Global Nosocomial Infection Control Market is projected to reach USD 53.78 billion by 2021 and is growing at a CAGR of 8.3% during the forecast period from 2017 to 2021. Hospital acquired infections are also called as nosocomial infections and are acquired in hospitals and other healthcare facilities. These infections can occur up to 48 hours after hospital admission or up to 3 days after discharge or up to 30 days after an operation or in a healthcare facility, when the patient was admitted for reasons other than infection.

In the geographical analysis, North America is the leading market for hospital acquired bacterial infections treatment and testing market. Due to stringent hospital regulatory policies and increased government initiatives to prevent and control various hospital-acquired infections, this region is able to maintain its dominant position across the world. Europe closely follows North America is terms of growth, due to increasing incidence of hospital-acquired infections. According to the Health Protection Agency (HPA) approximately of patients in hospitals in England acquire some form of bacterial infection during their hospital stay. However, other regions such as South East Asia, Middle East and Latin America are expected to be the promising markets in the near future. Owing to the rising disposable income among population, increasing incidence of bacterial infections and developing healthcare infrastructure, these regions are expected to be the potential market in the near future.

Past Conference Report

NHAI 2017: Past Conference Report

Conferenceseries LLC organized the International Congress on Nosocomial and Healthcare Associated Infections October 02-04, 2017 Las Vegas, Nevada, USA. The conference organized with a focus on Exploring the Challenges and Innovations in Outbreak Prevention and Control was a great success where eminent keynote speakers from various reputed institutions with their magnificent presence addressed the gathering.
The conference was commenced with an opening ceremony followed by Keynote sessions and followed by series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promote the theme with their elegant talk were:
           R. Scott Hatfield      Infection Prevention Products Inc., USA
           Jörg Imberger         University of Miami,USA
           Mahboob Quershi   Toruo University Nevada,USA
           Chih-Hung Ku         Kainan University,Taiwan              
           Stephen Hsu            Augusta University,USA
Conferenceseries LLC offers its heartfelt appreciation to Organizing Committee Members, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Conferenceseries LLC and supported the conference in every aspect, without which the conference would not have been possible.
Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of NHAI 2017, Conferenceseries LLC would like to announce the commencement of the “2nd  International Congress on Nosocomial and Healthcare Associated Infections” to be held during October 15-16, 2018 Las Vegas, Nevada, USA. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Nosocomial infections 2018.

To Collaborate Scientific Professionals around the World

Conference Date October 15-16,2018

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by